These results add to our understanding of drivers of response to PI3K-AKT inhibition in ER+ BC and the value of FOXO3 and FOXM1 as pharmacodynamic biomarkers for drugs targeting the PI3K-AKT pathway alone or in combination. Here, FOXO3 is linked to breast cancer.